Skip to main content
. Author manuscript; available in PMC: 2019 Apr 20.
Published in final edited form as: ACS Chem Biol. 2018 Mar 13;13(4):1013–1020. doi: 10.1021/acschembio.8b00199

Figure 2.

Figure 2

Accumulation within lysosomes reduces ferrostatin potency. (A) Decreasing EC50 of ferrostatin-1 mediated erastin (10 μM) rescue in the presence of 0, 5, and 10 μM chloroquine. Viability was measured at 24 h after compound treatment. Column height represents EC50 value with error bars corresponding to the 95% confidence interval. (B) Structure of lysosome-targeted ferrostatin 3 and SRS-compatible lysosome targeted ferrostatin 4. (C) Potency of ferrostatins in suppressing ferroptosis initiated by erastin (10 μM). (D) Signal in live HT-1080 cells treated with erastin and ferrostatins 2 or 4 (10 μM each, 6 h) and LysoTracker Red (100 nM, 30 min). Scale bars, 10 μM.